In a concluding remark, the anti-proliferative and anti-tumor potential of synthesized azomethine scaffold, BCS3, was elucidated against in vitro and in vivo breast cancer cells by antagonizing IAPs to regulate MDM2-p53 and Bcl-2-caspase axes that potentiated intrinsic and extrinsic apoptotic pathways after the determination of its promising binding affinity with the BIR3 domain of IAPs through in silico molecular docking studies. This evidence concerns the gene BCL2 and breast cancer.